365telugu.com online news,New Delhi, August 1st , 2025: The Pharmaceuticals Export Promotion Council of India (Pharmexcil), with support from the Ministry of Commerce & Industry, will organize the 11th edition of iPHEX—India’s flagship international pharmaceutical and healthcare exhibition—from September 4–6, 2025, at Bharat Mandapam, New Delhi.
iPHEX 2025 will bring together over 700 exhibitors and 25,000 domestic visitors, featuring a vibrant platform for business networking, policy dialogue, and strategic collaboration. The event is expected to attract delegates from 111+ countries, including key regulators and global buyers.
As the premier healthcare export summit, iPHEX 2025 will showcase India’s strengths across pharmaceutical formulations, biosimilars, bulk drugs, surgical products, and allied segments such as Ayush and pharma machinery. It will serve as a major milestone in India’s ambition to become a $65 billion pharma export powerhouse by 2030.
Key Highlights of iPHEX 2025:
- 700+ stalls dedicated to innovation, R&D, and exports
- Global Buyers-Sellers Meet for focused B2B engagements
- Global Regulators Conclave by CDSCO and Pharmexcil to foster regulatory alignment
- CEO Roundtable & Sectoral Panels on trade strategy, innovation, and pharma policy
- Focus Areas: Speciality generics, vaccines, biologics, CDMO/CRO services, gene therapies, and personalised medicine
- Target Market Outreach: NAFTA, EU, ASEAN, CIS, Africa, LAC, WANA
Since its inception in 2013, iPHEX has hosted 5,000+ foreign delegates and 4,000+ Indian exhibitors across major cities like Mumbai, Hyderabad, Ahmedabad, and New Delhi. It has emerged as a cornerstone of the Brand India Pharma campaign and plays a critical role in strengthening India’s identity as the “Pharmacy of the World.”
Pharmexcil Chairman Namit Joshi noted that iPHEX 2025 will offer “an exclusive environment for one-on-one business meetings, regulatory interactions, and strategic partnerships,” adding that the event is expanding its scope to include machinery and Ayush products for greater relevance.
Read This also…L&T Bags Major EPC Contract from Hindustan Zinc for Debari Smelter Expansion
Vice Chairman Bhavin Mehta emphasized iPHEX’s role in trade diplomacy and said the summit will “go beyond the traditional exhibition model, driving deep engagement across technology transfers, contract manufacturing, and market collaborations.”
Pharmexcil Director General K Raja Bhanu remarked that India’s pharma growth is driven by its proven strengths in quality, affordability, and scalability, and the path forward will include bold investments, regulatory harmonization, and innovation in advanced therapies. “iPHEX 2025 is not just an event—it is a vision for Bharat @2030,” he added.
With sector-specific sessions, regulatory conclaves, and global buyer forums, iPHEX 2025 is poised to fuel India’s trajectory in global healthcare diplomacy, bridging markets and powering the next wave of pharmaceutical exports.